GSK’s cancer drug Blenrep, combined with bortezomib and dexamethasone, significantly reduces the death risk in relapsed multiple myeloma by 42%. The DREAMM-7 trial shows better survival rates compared to the standard daratumumab combination. Patients on Blenrep may live nearly three years longer, offering new hope for treating this blood cancer.
Read more: Karachi Schools Introduce Free Medical Check-Ups And Daily Breakfast
After facing setbacks, Blenrep is now preparing for a comeback. The DREAMM-7 and DREAMM-8 trials highlight its potential to redefine treatment options. GSK plans five major drug launches in 2025, including Blenrep, which could achieve peak sales of over £3 billion. Hesham Abdullah, GSK’s head of oncology, called the results a significant advancement in multiple myeloma care.
Stay tuned to Brandsynario for the latest news and updates.